SignaBlok awarded NEI / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitors for neovascular retinal diseases
SignaBlok awarded NHLBI / NIH SBIR Phase I grant to develop new mechanism-based TREM-1 therapy for acute respiratory distress syndrome
SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.
SignaBlok awarded NIAMS / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitor for treatment of rheumatoid arthritis
SignaBlok awarded DoD SBIR Phase I contract to support new technology to prevent the effects of acute radiation syndrome
SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer
SignaBlok awarded NIGMS / NIH SBIR Phase I grant to test novel TREM-1 therapy for treatment of sepsis
SignaBlok awarded NEI / NIH SBIR Phase I grant to test new approach to prevention and treatment of neovascular retinal diseases
SignaBlok awarded NCI / NIH SBIR Phase I grant to test first-in-class TREM-1 inhibitor in combination with chemotherapy for treatment of pancreatic cancer